Realizing the potential of tissue-targeted RNA therapies

miRecule™ is a biotechnology company developing RNA therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders.

 

Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality.

 

miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy.

 

miRecule, Inc. Announces Issuance of New Patent Broadly Covering Lead RNA Therapeutics

GAITHERSBURG, MD – October 1, 2024 – miRecule, a biopharmaceutical company focused on developing antibody RNA conjugate-based therapeutics for rare genetic diseases and other conditions, today announced the issuance of U.S. Patent No. 12,104,157, titled "Targeted...

Mirecule Wins MedCity INVEST 2024 Competition

Chicago, May 2024 — miRecule, a cutting-edge startup focused on developing antibody RNA conjugate therapeutics, clinched the top spot at the prestigious MedCity INVEST Biopharma track competition held at the Ritz Carlton in Chicago. The event, presented by MedCity...

miRecule and Sanofi discuss the potential of RNA Therapeutics for treatment of Rare Diseases

miRecule and Sanofi have partnered to pioneer innovative approaches in rare diseases and advance a novel RNA therapeutic for patients with the genetic disorder FSHD. miRecule’s DREAmiR™ discovery platform, combined with Sanofi’s Nanobody® technology, enables the...

miRecule Enters into Strategic Collaboration with Sanofi to Accelerate Discovery and Development of a Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

Partnership combines miRecule’s unique RNA therapeutic discovery and conjugation platforms with Sanofi’s NANOBODY® technology to create a groundbreaking treatment for FSHD miRecule will receive an upfront payment with potential future milestone payments of nearly $400...

SOLVE FSHD Invests US $1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA Conjugate to Treat Facioscapulohumeral Muscular Dystrophy

Read the press release here: SOLVE-FSHD Invests US 1 Million in miRecule to Accelerate Development of Best-in-Class Antibody-RNA-Conjugate to Treat Facioscapulohumeral Muscular Dystrophy_

miRecule Inc. closes $5.7M to create breakthrough RNA therapies for cancer & muscular dystrophy

Read the full story here: Global News Wire